BINGE BEHAVIOR REGULATORS

1 . A method of regulating binge behavior, the method comprising administrating to a subject in need thereof a compound represented by Formula I:

wherein:

each of R 1 and R 2 is independently selected from the group consisting of H, (C 1 -C 8 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, —O(C 1 -C 6 )alkyl, OH, —OS(═O) 2 CF 3 , —OS(═O) 2 -(C 1 -C 6 )alkyl, —S(═O)R 5 , —CO 2 R 5 , —CONR 5 R 6 , —COR 5 , —CF 3 , CN, —SR 5 , —SO 2 NR 5 R 6 , —SO 2 R 5 , —OCO—(C 1 -C 6 )alkyl, —NCO-(C 1 -C 6 )alkyl, —CH 2 O—(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkyl-OH, and halogen, or, alternatively, R 1 and R 2 together with two or more of the phenyl carbon atoms form a X 1 —(CR 5 R 6 ) m- —X 2 -ring, wherein each of X 1 and X 2 is independently selected from O, NH or S and m is 1, 2, 3, or 4;

each of R 3 and R 4 is independently selected from the group consisting of H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )cycloalkyl, and —(CH 2 ) p -thienyl, wherein p is 1, 2, 3, or 4, or alternatively, R 3 and R 4 are joined together to form a heterocylic ring (heteroalicyclic or heteroaryl) containing the nitrogen atom to which they are attached; and

each of R 5 and R 6 is independently selected from the group consisting of H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 3 -C 8 )cycloalkyl and aryl,

thereby regulating the binge behavior.

2 . The method of claim 1 , wherein said binge behavior is associated with alcohol consumption, eating, tobacco consumption, shopping or sexual conduct.

3 . The method of claim 2 , wherein said binge behavior is binge drinking.

4 . The method of claim 1 , wherein said compound forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.

5 . The method of claim 4 , wherein said composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate or a syrup.

6 . The method of claim 4 , wherein said composition is a unit dosage form composition.

7 . The method of claim 6 , wherein an amount of said compound in said unit dosage form ranges from 30 mg to 130 mg.

8 . The method of claim 7 , wherein said amount of said compound is 70 mg.

9 . The method of claim 1 , wherein said compound or composition is administered to a subject orally.

10 . The method of claim 1 , wherein at least one of R 3 and R 4 is H.

11 . The method of claim 1 , wherein the compound of Formula I is selected from:

5-methoxy-2-aminoindan;

5,6-dimethoxy-2-aminoindan;

5-methoxy-2-(N-propylamino)indan;

5,6-dimethoxy-2-(N-propylamino)indan;

5,6-dimethoxy-2-(di-N-butylamino)indan;

5-(trifluoromethylsulfonyloxy)-2-(N-propylamino)indan;

5,6-(di-trifluoromethylsulfonyloxy)-2-(N-propylamino)Indan;

5,6-dimethoxy-2 (pyrrolidino)indan;

5-(trifluoromethylsulfonyloxy)-6-hydroxy-2-(di-N-propylamino)indan;

5-(triluuoromethylsulfonyloxy)-6-acetoxy-2-(di-N-propylamino)indan;

5-trifluromethansulfonyloxy-6-methoxy-2-(di-N-propylamino)indan;

5,6-ethylenedioxy-2-(di-N-propylamino)indan; and

5,6-methylenedioxy-2-(di-N-propylamino)indan.

12 . The method of claim 1 , wherein the compound of Formula I is 5-methoxy-2-aminoindan.

13 . A pharmaceutical composition comprising a compound represented by Formula I:

wherein:

each of R 1 and R 2 is independently selected from the group consisting of H, (C 1 -C 8 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )cycloalkyl, aryl, heteroaryl, heteroalicyclic, —O(C 1 -C 6 )alkyl, OH, —OS(═O) 2 CF 3 , —OS(═O) 2 -(C 1 -C 6 )alkyl, —S(═O)R 5 , —CO 2 R 5 , —CONR 5 R 6 , —COR 5 , —CF 3 , CN, —SR 5 , —SO 2 NR 5 R 6 , —SO 2 R 5 , —OCO—(C 1 -C 6 )alkyl, —NCO-(C 1 -C 6 )alkyl, —CH 2 O-(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkyl-OH, and halogen, or, alternatively, R 1 and R 2 together with two or more of the phenyl carbon atoms form a X 1 —(CR 5 R 6 ) m- —X 2 -ring, wherein each of X 1 and X 2 is independently selected from O, NH or S and m is 1, 2, 3, or 4;

each of R 3 and R 4 is independently selected from the group consisting of H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 8 )cycloalkyl, and —(CH 2 ) p -thienyl, wherein p is 1, 2, 3, or 4, or alternatively, R 3 and R 4 are joined together to form a heterocylic ring (heteroalicyclic or heteroaryl) containing the nitrogen atom to which they are attached; and

each of R 5 and R 6 is independently selected from the group consisting of H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 3 -C 8 )cycloalkyl and aryl.

14 . The pharmaceutical composition of claim 13 , being a unit dosage from composition.

15 . The pharmaceutical composition of claim 14 , being a solid unit dosage form composition.

16 . The pharmaceutical composition of claim 14 , being a liquid unit dosage form composition.

17 . The pharmaceutical composition of claim 14 , being packaged as a single unit dose or as a plurality of single unit doses.

18 . The pharmaceutical composition of claim 14 , wherein said unit dosage form comprises from 30 mg to 130 mg of said compound.

19 . The pharmaceutical composition of claim 13 , formulated for oral administration.

20 . The pharmaceutical composition of claim 13 , wherein at least one of R 3 and R 4 is H.

21 . The pharmaceutical composition of claim 13 , wherein the compound of Formula I is selected from:

5-methoxy-2-aminoindan;

5,6-dimethoxy-2-aminoindan;

5-methoxy-2-(N-propylamino)indan;

5,6-dimethoxy-2-(N-propylamino)indan;

5,6-dimethoxy-2-(di-N-butylamino)indan;

5-(trifluoromethylsulfonyloxy)-2-(N-propylamino)indan;

5,6-(di-trifluoromethylsulfonyloxy)-2-(N-propylamino)Indan;

5,6-dimethoxy-2 (pyrrolidino)indan;

5-(trifluoromethylsulfonyloxy)-6-hydroxy-2-(di-N-propylamino)indan;

5-(triluuoromethylsulfonyloxy)-6-acetoxy-2-(di-N-propylamino)indan;

5-trifluromethansulfonyloxy-6-methoxy-2-(di-N-propylamino)indan;

5,6-ethylenedioxy-2-(di-N-propylamino)indan; and

5,6-methylenedioxy-2-(di-N-propylamino)indan.

22 . The pharmaceutical composition of claim 13 , wherein the compound of Formula I is 5-methoxy-2-aminoindan.